Immunotherapy summit brings together patients, experts - Jan. 11, 2018 
The NCI-designated Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine is hosting a free educational program for cancer patients and their caregivers seeking to learn more about cancer immunotherapy and clinical trials.

How immunotherapy is transforming cancer treatment and patient care - Oct. 16, 2017 
Dr. Andrew Sikora, vice chair of research in the Department of Otolaryngology and co-director of the head and neck cancer program at Baylor, breaks down exactly what immunotherapy does to the body to treat cancer.

NewsLink: Sikora named to cancer groups - Dec. 16. 2016 
Dr. Andrew Sikora, associate professor of otolaryngology and Carolyn Weiss Law Translational Research Scholar, recently was appointed to the steering committee of two national cooperative trials groups.

Oral, head and neck cancer and HPV: What you should know - April 13, 2016 
Dr. Robert Ferris, chief of the division of head and neck surgery at the University of Pittsburgh Cancer Institute and Dr. Andrew Sikora, vice chair for research and co-director of Baylor College of Medicine’s Head and Neck Cancer Program, discuss oropharyngeal cancer prevention and treatment.

Baylor College of Medicine receives grant to study experimental immunotherapy in HPV-related throat cancer - Sept. 2015
Baylor researchers receive $1.1 million grant from the U.S. Food and Drug Administration to advance clinical studies of an experimental immunotherapy for HPV related throat cancer.

Baylor’s Dan L Duncan Cancer Center receives highest National Cancer Institute designation – Comprehensive status - July 30, 2015
The National Cancer Institute has awarded the Dan L Duncan Cancer Center at Baylor College of Medicine the prestigious designation of a Comprehensive Cancer Center.

Your immune system: The secret weapon against HPV-related cancers - April 13, 2015 
Dr. Andrew Sikora, associate professor of Otolaryngology and co-director of the Baylor College of Medicine Head and Neck Cancer Program discusses eradicating HPV-related cancers using the patient's own immune system.

Future Looks Promising for Immunotherapy in Head and Neck Cancer - Nov. 6, 2014 
Both HPV-positive and -negative head and neck cancers are “outstanding candidates for immunotherapeutic strategies,” says Andrew G. Sikora.

Immune-related gene may predispose to HPV-related cancer - Oct. 23, 2014
Baylor-led research identifies immune related gene that appears to play an important role in determining whether a person develops a cancer related to human papilloma virus.